Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Transplant. 2011 May;15(3):229-36. doi: 10.1111/j.1399-3046.2010.01454.x. Epub 2010 Dec 27.

Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation.

Author information

1
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15224, USA. judy.martin@chp.edu

Abstract

Cytomegalovirus (CMV) is an important cause of morbidity and mortality in children who have received organ transplants. Patients have been reported to be at differential risk for CMV disease based on the serostatus of the donor and recipient with highest risk reported for CMV seronegative recipients who receive an organ from a CMV seropositive donor. Prophylaxis with ganciclovir and/or oral valganciclovir is reasonable to attempt to prevent CMV infections. A hybrid strategy bridging prophylaxis and pre-emptive therapy appears to be emerging as an additional method to prevent CMV disease. However, there is no agreement on the optimal schedule of testing, duration and dosing of antiviral medications or the role of immunoglobulin therapy. This manuscript will review the most recent literature and recommendations for the prophylaxis and treatment of CMV infections and disease in pediatric transplant recipients. Multicenter, randomized, clinical studies involving several pediatric transplant centers are needed to determine the best strategies to prevent and treat CMV infections in these patients.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center